Value of alpha-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus

Florine Kastelein; Katharina Biermann; Ewout Steyerberg; Joanne Verheij; Marit Kalisvaart; LHJ (Leendert) Looijenga; Hans Stoop; L Walter; Ernst Kuipers; Manon Spaander; Marco Bruno

doi:10.1111/his.12216

Value of alpha-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus

Florine Kastelein, Katharina Biermann, Ewout Steyerberg, Joanne Verheij, Marit Kalisvaart, LHJ (Leendert) Looijenga, Hans Stoop, L Walter, Ernst Kuipers, Manon Spaander, Marco Bruno

Research output: Contribution to journal › Article › Academic › peer-review

26 Citations (Scopus)

Abstract

AimTo investigate the value of -methylacyl-CoA racemase (AMACR) immunohistochemistry for predicting neoplastic progression in Barrett's oesophagus (BO). Methods and resultsWe conducted a case-control study within a prospective cohort of 720 BO patients. Patients who developed high-grade dysplasia or oesophageal adenocarcinoma were classified as cases, and patients without neoplastic progression as controls. AMACR expression was determined by immunohistochemistry in 12127 biopsies from 635 patients, and was scored independently by two expert pathologists. Relative risks adjusted for age, gender, BO length and oesophagitis (RRa) were calculated in ConclusionsStrong AMACR expression is associated with an increased risk of neoplastic progression in BO. However, AMACR expression appears to be a less powerful predictor for neoplastic progression than low-grade dysplasia.

Original language	Undefined/Unknown
Pages (from-to)	630-639
Number of pages	10
Journal	Histopathology
Volume	63
Issue number	5
DOIs	https://doi.org/10.1111/his.12216
Publication status	Published - 2013

Access to Document

10.1111/his.12216

http://hdl.handle.net/1765/41362

Cite this

@article{95bfb390a0ae41879535eab4904c1fc5,

title = "Value of alpha-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus",

abstract = "AimTo investigate the value of -methylacyl-CoA racemase (AMACR) immunohistochemistry for predicting neoplastic progression in Barrett's oesophagus (BO). Methods and resultsWe conducted a case-control study within a prospective cohort of 720 BO patients. Patients who developed high-grade dysplasia or oesophageal adenocarcinoma were classified as cases, and patients without neoplastic progression as controls. AMACR expression was determined by immunohistochemistry in 12127 biopsies from 635 patients, and was scored independently by two expert pathologists. Relative risks adjusted for age, gender, BO length and oesophagitis (RRa) were calculated in ConclusionsStrong AMACR expression is associated with an increased risk of neoplastic progression in BO. However, AMACR expression appears to be a less powerful predictor for neoplastic progression than low-grade dysplasia.",

author = "Florine Kastelein and Katharina Biermann and Ewout Steyerberg and Joanne Verheij and Marit Kalisvaart and Looijenga, {LHJ (Leendert)} and Hans Stoop and L Walter and Ernst Kuipers and Manon Spaander and Marco Bruno",

year = "2013",

doi = "10.1111/his.12216",

language = "Undefined/Unknown",

volume = "63",

pages = "630--639",

journal = "Histopathology",

issn = "0309-0167",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "5",

}

TY - JOUR

T1 - Value of alpha-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus

AU - Kastelein, Florine

AU - Biermann, Katharina

AU - Steyerberg, Ewout

AU - Verheij, Joanne

AU - Kalisvaart, Marit

AU - Looijenga, LHJ (Leendert)

AU - Stoop, Hans

AU - Walter, L

AU - Kuipers, Ernst

AU - Spaander, Manon

AU - Bruno, Marco

PY - 2013

Y1 - 2013

N2 - AimTo investigate the value of -methylacyl-CoA racemase (AMACR) immunohistochemistry for predicting neoplastic progression in Barrett's oesophagus (BO). Methods and resultsWe conducted a case-control study within a prospective cohort of 720 BO patients. Patients who developed high-grade dysplasia or oesophageal adenocarcinoma were classified as cases, and patients without neoplastic progression as controls. AMACR expression was determined by immunohistochemistry in 12127 biopsies from 635 patients, and was scored independently by two expert pathologists. Relative risks adjusted for age, gender, BO length and oesophagitis (RRa) were calculated in ConclusionsStrong AMACR expression is associated with an increased risk of neoplastic progression in BO. However, AMACR expression appears to be a less powerful predictor for neoplastic progression than low-grade dysplasia.

AB - AimTo investigate the value of -methylacyl-CoA racemase (AMACR) immunohistochemistry for predicting neoplastic progression in Barrett's oesophagus (BO). Methods and resultsWe conducted a case-control study within a prospective cohort of 720 BO patients. Patients who developed high-grade dysplasia or oesophageal adenocarcinoma were classified as cases, and patients without neoplastic progression as controls. AMACR expression was determined by immunohistochemistry in 12127 biopsies from 635 patients, and was scored independently by two expert pathologists. Relative risks adjusted for age, gender, BO length and oesophagitis (RRa) were calculated in ConclusionsStrong AMACR expression is associated with an increased risk of neoplastic progression in BO. However, AMACR expression appears to be a less powerful predictor for neoplastic progression than low-grade dysplasia.

U2 - 10.1111/his.12216

DO - 10.1111/his.12216

M3 - Article

VL - 63

SP - 630

EP - 639

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 5

ER -